Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:BCEL

Atreca (BCEL) Stock Price, News & Analysis

Atreca logo

About Atreca Stock (NASDAQ:BCEL)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$0.09
$0.09
50-Day Range
$0.09
$0.09
52-Week Range
$0.05
$1.20
Volume
N/A
Average Volume
4.61 million shs
Market Capitalization
$3.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

Remove Ads
Receive BCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atreca and its competitors with MarketBeat's FREE daily newsletter.

BCEL Stock News Headlines

Musk’s real agenda in D.C.
In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of America…
Atreca, Inc. (0C1.MU)
Atreca Inc. Cl A
Atreca Stock (NASDAQ:BCEL), Short Interest Report
See More Headlines

BCEL Stock Analysis - Frequently Asked Questions

Atreca, Inc. (NASDAQ:BCEL) posted its earnings results on Tuesday, November, 2nd. The company reported ($0.74) earnings per share for the quarter, meeting the consensus estimate of ($0.74).

Atreca (BCEL) raised $126 million in an initial public offering on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Atreca investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Micron Technology (MU), Alector (ALEC), Advanced Micro Devices (AMD), PayPal (PYPL) and Meta Platforms (META).

Company Calendar

Last Earnings
11/02/2021
Today
3/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BCEL
Fax
N/A
Employees
130
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-97,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.01 per share
Price / Book
0.04

Miscellaneous

Free Float
35,146,000
Market Cap
$3.57 million
Optionable
Optionable
Beta
1.03
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:BCEL) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners